# History and Physical

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Nelson Mandela (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML021-SYN-TD
- Date: 2001-03-10
- Fictional facility: St. Posthumous Health Center
- Fictional author: Thandiwe Mokoena, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## Reason for visit

First visit after a biopsy diagnosis of localized prostate cancer: risk group, staging, baseline before treatment, and radiation oncology referral. **S**

## Historical basis

- Nelson Rolihlahla Mandela was born in Mvezo, in the Eastern Cape, on 18 July 1918. **D**
- Mandela was convicted with seven co-accused in the Rivonia Trial on 11 June 1964 and sentenced to life imprisonment the next day. He was held on Robben Island, moved to Pollsmoor Prison on 31 March 1982 and to Victor Verster Prison near Paarl on 7 December 1988, and was released from Victor Verster on 11 February 1990. **D**
- In 1985 Mandela had prostate surgery while imprisoned. His urologist said in July 2001 that the gland had been enlarged and was causing a urinary blockage, and that part of it was removed. **D**
- Mandela was taken to hospital on 12 August 1988 and diagnosed with tuberculosis; public reports describe it as early tuberculosis, treated at the Constantiaberg Medi-clinic, after which he was moved to Victor Verster Prison. **D**
- His doctors said publicly in 2001 that he had been monitored regularly with the prostate-specific antigen (PSA) test, that a slight rise in the PSA led to a biopsy of the prostate, and that the biopsy confirmed microscopic cancer within the gland. News reports said the raised blood level was first found in November 2000. **D**
- Mandela was inaugurated as South Africa's first democratically elected president on 10 May 1994 and stepped down in 1999 after one term. **D**

4 later historical claims are omitted because they describe events after the index age. See the teaching note.

These claims are historical evidence, not findings from a real modern examination.

## History of present illness

This fictional modern episode addresses the presenting concerns below. **S**

- Wants to understand a new diagnosis of prostate cancer after a rising PSA, and what treatment would mean at his age and with his commitments. **S**
- Wants to keep his travel and public work going during treatment. **S**

## Strengths and supports

- Supports: family, close friends, and a personal assistant who manages his schedule **S**

## Medications and allergies

- No medications before this visit. **S**
- No known allergy **S**

## Past medical history

True biography with historical dates; these events are not part of the synthetic care timeline.

- 1985: Operation on the prostate for an enlarged gland causing urinary blockage, with part of the gland removed (type of operation not recorded in the cited sources) **D** (CLM-0003)
- 12 August 1988: Tuberculosis, diagnosed after admission to hospital and treated **D** (CLM-0004)
- November 2000: Raised PSA found on routine monitoring, followed by a prostate biopsy **D** (CLM-0005)

## Procedures and immunizations

- 2001-01-20 to 2001-01-20: Multiparametric MRI of the prostate: gland volume 28 mL with a resection defect from the earlier operation; 9 mm PI-RADS 4 lesion in the left peripheral zone at the mid-gland; no extraprostatic extension, seminal vesicle invasion, or enlarged pelvic nodes **S**
- 2001-02-10 to 2001-02-10: MRI-ultrasound fusion transperineal biopsy of the prostate, at the urology practice: adenocarcinoma, Gleason 4+3 (Grade Group 3) in 1 of 2 targeted cores (30 percent of the core) and in 2 of 12 systematic cores (Gleason 3+4, 10 and 15 percent); 3 of 14 cores in all; no perineural invasion **S**
- 2000-10-21: High-dose influenza vaccine, last season **S**
- 1994-05-14: Tdap vaccine **S**

## Family history

- No family medical history is documented in the logged sources. Family history of real relatives is never synthesized.

## Measurements

PSA: 6.4 ng/mL (high); Total testosterone: 412 ng/dL; Hemoglobin: 14.1 g/dL; White cell count: 5.8 10*3/uL; Platelets: 226 10*3/uL; Sodium: 140 mmol/L; Potassium: 4.4 mmol/L; Fasting glucose: 94 mg/dL; Creatinine: 1.08 mg/dL; eGFR: 69 mL/min/1.73 m²; Calcium: 9.4 mg/dL; ALT: 18 U/L; Alkaline phosphatase: 74 U/L; Albumin: 4.1 g/dL; Hemoglobin A1c: 5.5%; Total cholesterol: 184 mg/dL; HDL cholesterol: 52 mg/dL; LDL cholesterol: 112 mg/dL; Triglycerides: 98 mg/dL; 25-hydroxyvitamin D: 26 ng/mL (low); PHQ-9: 4; IPSS total (0 to 35): 7. All results are synthetic.

BP 132/78 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 97% on room air; weight 80.2 kg; BMI 23.9 kg/m². All vital signs are synthetic.

## Examination

Mental status: Alert, warm, and composed; asks direct questions and wants to weigh the treatment options himself; Mood good; PHQ-9 minimal at the first visit. Functional status: Independent in all activities and instrumental activities of daily living; Walks 30 to 45 minutes most mornings. Physical examination is intentionally limited. **S**

## Assessment

1. Adenocarcinoma of the prostate, NCCN unfavorable intermediate risk: cT1c, Grade Group 3 (Gleason 4+3), PSA 6.4 ng/mL, 3 of 14 cores, found after a rising PSA; synthetic modern detail linked to his publicly announced prostate cancer; status draft. **S**
2. Hormone-sensitive prostate cancer; status draft. **S**

## Plan

- Radiation oncology consultation to review staging and discuss curative treatment options and short-term androgen deprivation. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022) **S**
- Staging for unfavorable intermediate-risk disease with PSMA PET/CT. Guideline: NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**
- Distress screening at each visit, physical activity, and a written survivorship care plan. Guideline: Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014); CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026) **S**

## Guideline basis

- NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer (2026), National Comprehensive Cancer Network
- Eastham JA, et al. Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging, and Risk-Based Management. J Urol 2022;208(1):10-18 (2022), American Urological Association and American Society for Radiation Oncology
- Skolarus TA, et al. American Cancer Society prostate cancer survivorship care guidelines. CA Cancer J Clin 2014;64(4):225-249 (2014), American Cancer Society
- CMID: Clinical Monitoring Intelligence Database, prostate cancer monograph (2026), Aether Forge
